AgingResearch.NewsJoin free

Trametinib + navitoclax

Trametinib + navitoclax has been studied in 2 papers since 2026: none in people yet, 2 in animals; 2 in the past year. The research so far is in animals. The newest story, Oct 29, 2026: “Drug combination limited brain tumor regrowth in mice”.

Intervention

2 papers study it1 more mentions it5 findingsUpdated

PubChemPubChemChEBIChEBI

1 new paper in 30 daysSee all 3

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: Brain Tumour Charity and 6 more
  • Animals2

What did studies of Trametinib + navitoclax find?

5

Studies of Trametinib + navitoclax measured 5 outcomes; the most studied are survival (1 study), tumor regrowth (1) and senescent tumor cells (1).

Survival

upin mice1

1 study

  1. Trametinib + navitoclax improves survival in mice (pediatric BRAF-V600E glioma).

    “combined Trametinib and Navitoclax treatment ablated senescent tumour cells, significantly reduced tumour regrowth after treatment withdrawal, and improved survival.”

    Animalspediatric BRAF-V600E glioma

    Drug combination limited brain tumor regrowth in mice

    Neuro-oncology

Tumor regrowth

downin mice1

1 study

  1. Trametinib + navitoclax decreases tumor regrowth in mice after treatment withdrawal in pediatric BRAF-V600E glioma.

    “combined Trametinib and Navitoclax treatment ablated senescent tumour cells, significantly reduced tumour regrowth after treatment withdrawal, and improved survival.”

    Animalsafter treatment withdrawal in pediatric BRAF-V600E gliomatumor

    Drug combination limited brain tumor regrowth in mice

    Neuro-oncology

Senescent tumor cells

downin mice1

1 study

  1. Trametinib + navitoclax decreases senescent tumor cells in mice (pediatric BRAF-V600E glioma).

    “In vivo, combined Trametinib and Navitoclax treatment ablated senescent tumour cells”

    Animalspediatric BRAF-V600E gliomatumor

    Drug combination limited brain tumor regrowth in mice

    Neuro-oncology

More on Senescent tumor cells

Mouse survival

upin mice1

1 study

  1. Trametinib + navitoclax increases mouse survival in mice (BT-40 tumour-bearing mice).

    “combination of Trametinib and Navitoclax causes the ablation of senescent BT-40 cells with significant reduction in tumour regrowth after treatment withdrawal and increased mouse survival”

    AnimalsBT-40 tumour-bearing mice

    Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

Tumour regrowth after treatment withdrawal

downin mice1

1 study

  1. Trametinib + navitoclax decreases tumour regrowth after treatment withdrawal in mice (BT-40 tumour-bearing mice, after treatment withdrawal).

    “combination of Trametinib and Navitoclax causes the ablation of senescent BT-40 cells with significant reduction in tumour regrowth after treatment withdrawal”

    AnimalsBT-40 tumour-bearing mice, after treatment withdrawal

    Standard treatment against paediatric BRAF-V600E glioma promotes senescence and sensitizes tumours to BCL-xL inhibition

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 12 papers in 12 months
Neuro-oncology

Drug combination limited brain tumor regrowth in mice

In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.

Mouse studyInterventions
Paper

Related